1. Name Of The Medicinal Product
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
Retacrit
2. Qualitative And Quantitative Composition
1 pre-filled syringe with 0.3 ml solution for injection contains 1000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 3333 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.6 ml solution for injection contains 2000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 3333 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.9 ml solution for injection contains 3000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 3333 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.4 ml solution for injection contains 4000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 10000 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.5 ml solution for injection contains 5000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 10000 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.6 ml solution for injection contains 6000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 10000 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.8 ml solution for injection contains 8000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 10000 IU Epoetin zeta per ml.
1 pre-filled syringe with 1.0 ml solution for injection contains 10000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 10000 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.5 ml solution for injection contains 20000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 40000 IU Epoetin zeta per ml.
1 pre-filled syringe with 0.75 ml solution for injection contains 30000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 40000 IU Epoetin zeta per ml.
1 pre-filled syringe with 1.0 ml solution for injection contains 40000 international units (IU) epoetin zeta* (recombinant human erythropoietin). The solution contains 40000 IU Epoetin zeta per ml.
*Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell line.
Excipient:
Retacrit 1000 IU/0.3 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.15 mg phenylalanine.
Retacrit 2000 IU/0.6 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.30 mg phenylalanine
Retacrit 3000 IU/0.9 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.45 mg phenylalanine
Retacrit 4000 IU/0.4 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.20 mg phenylalanine
Retacrit 5000 IU/0.5 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.25 mg phenylalanine
Retacrit 6000 IU/0.6 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.30 mg phenylalanine
Retacrit 8000 IU/0.8 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.40 mg phenylalanine
Retacrit 10000 IU/1.0 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.50 mg phenylalanine
Retacrit 20000 IU/0.5 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.25 mg phenylalanine
Retacrit 30000 IU/0.75 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.38 mg phenylalanine
Retacrit 40000 IU/1.0 ml solution for injection in pre-filled syringe: Each pre-filled syringe contains 0.50 mg phenylalanine
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Solution for injection in pre
Clear, colourless solution.
4. Clinical Particulars
4.1 Therapeutic Indications
- Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: | |
| |
- Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).
|
4.2 Posology And Method Of Administration
Treatment with Retacrit has to be initiated under the supervision of physicians experienced in the management of patients with above indications.
Posology
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients
Retacrit should be administered either subcutaneously or intravenously.
The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l). The upper limit of the target haemoglobin concentration should not be exceeded.
Anemia symptoms and sequaelea may vary with age, gender and overall burden of disesase; a physician´s evaluation of the individual patient´s clinical course and condition is necessary. Retacrit should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L) Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed. Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dL (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
A sustained haemoglobin level of greater than 12 g/dl should be avoided; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g/dl (7.5 mmol/l) are observed are described below. A rise in haemoglobin of greater than 2 g/dL (1.25 mmol/l) over a four week period should be avoided. If it occurs, appropriate dose adjustment should be made as provided.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of the symptoms of anemia.
In patients with chronic renal failure and clinically evident ischemic heart disease or congestive heart failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration.
Adult patients on haemodialysis
Retacrit should be administered either subcutaneously or intravenously.
The treatment is divided into two stages:
| 50 IU/kg 3 times per week. When a dose adjustment is necessary, this should be done in steps of at least four weeks. At each step, the increase or reduction in dose should be of 25 IU/kg 3 times per week. |
| Dose adjustment in order to maintain haemoglobin (Hb) values at the desired level: Hb between 10 and 12 g/dl (6.2-7.5 mmol/l). The recommended total weekly dose is between 75 and 300 IU/kg. |
The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6 g/dl or < 3.75 mmol/l) may require higher maintenance doses than those whose initial anaemia is less severe (Hb> 8 g/dl or> 5 mmol/l).
Paediatric patients on haemodialysis
The treatment is divided into two stages:
| 50 IU/kg, 3 times per week by the intravenous route. When a dose adjustment is necessary, this should be done in steps of 25 IU/kg, 3 times per week at intervals of at least 4 weeks until the desired goal is achieved. |
| Dose adjustment in order to maintain haemoglobin (Hb) values at the desired level: Hb between 9.5 and 11 g/dl (5.9-6.8 mmol/l). |
Generally, children and adolescents under 30 kg body weight require higher maintenance doses than adults and children over 30 kg. The following maintenance doses were observed in clinical trials after 6 months of treatment
| ||
|
|
|
|
|
|
|
|
|
|
|
|
The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/dl or < 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher> 6.8 g/dl or> 4.25 mmol/l).
Adult patients on peritoneal dialysis
Retacrit should be administered either subcutaneously or intravenously.
The treatment is divided into two stages:
| Starting dose of 50 IU/kg 2 times per week. |
2. Maintenance phase: | Dose adjustment in order to maintain haemoglobin (Hb) values at the desired level: Hb between 10 and 12 g/dl (6.2-7.5 mmol/l). Maintenance dose between 25 and 50 IU/kg 2 times per week into 2 equal doses. |
Adult patients with renal insufficiency not yet undergoing dialysis
Retacrit should be administered either subcutaneously or intravenously.
The treatment is divided into two stages:
| Starting dose of 50 IU/kg 3 times per week, followed if necessary by a dose increase with 25 IU/kg increments (3 times per week) until the desired goal is achieved (this should be done in steps of at least four weeks). |
2. Maintenance phase: | Dose adjustment in order to maintain haemoglobin (Hb) values at the desired level: Hb between 10 and 12 g/dl (6.2-7.5 mmol/l). Maintenance dose between 17 and 33 IU/kg 3 times per week. |
The maximum dose should not exceed 200 IU/kg 3 times per week.
Treatment of patients with chemotherapy induced anaemia..
Retacrit should be administered by the subcutaneous route to patients with anaemia (e.g. haemoglobin concentration
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed. Haemoglobin variability should be addressed through dose management with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l). A sustained haemoglobin level of greater than 12 g/dl (7.5 mmol/l) should be avoided; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g/dl (7.5 mmol/l) are observed are described below.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of the symptoms of anaemia.
Retacrit therapy should continue until one month after the end of chemotherapy.
The initial dose is 150 IU/kg given subcutaneously 3 times per week. Alternatively, Retacrit can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
If the haemoglobin has increased by at least 1 g/dl (0.62 mmol/l) or the reticulocyte count has increased
The recommended dosing regimen is described in the following diagram:
Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level. Appropriate dose titration should be considered.
Dose adjustment
At a rate of rise in haemoglobin of> 2 g/dl (> 1.25 mmol/l) per month the Retacrit dose should be reduced by about 25-50%. If haemoglobin level exceeds 12 g/dl (7.5 mmol/l), discontinue therapy until it falls to 12 g/dl (7.5 mmol/l) or lower and then reinstitute Retacrit therapy at a dose 25% below the previous dose.
Treatment of adult surgery patients in an autologous predonation programme.
Retacrit should be given by the intravenous route.
At the time of donating blood, Retacrit should be administered after the completion of the blood donation procedure.
Mildly anaemic patients (haematocrit of 33-39%) requiring predeposit of
All patients being treated with Retacrit should receive adequate iron supplementation (e.g. 200 mg oral elemental iron daily) throughout the course of treatment. Iron supplementation should be started as soon as possible, even several weeks prior to initiating the autologous predeposit, in order to achieve high iron stores prior to starting Retacrit therapy.
Treatment of adult patients scheduled for major elective orthopaedic surgery
Retacrit should be administered subcutaneously.
A dose of 600 IU/kg body weight should be administered once weekly for three weeks (on day 21, 14 and 7) prior to surgery and on the day of surgery (day 0). If the lead time before surgery needs to be shortened to less than three weeks, a dose of 300 IU/kg body weight should be given daily for 10 consecutive days prior to surgery, on the day of surgery, and for four days immediately thereafter. When performing haematologic assessments during the preoperative period, if the haemoglobin level reaches 15 g/dl, or higher, administration of Retacrit should be stopped and further doses should not be given.
Iron deficiencies should be treated prior to starting treatment with Retacrit. In addition, all patients should receive adequate iron supplementation (e.g. 200 mg oral elemental iron daily) throughout the course of Retacrit treatment. If possible, iron supplementation should be started prior to treatment with Retacrit, to achieve adequate iron stores.
Method of administration
For instructions on handling of the medicinal product before administration, see section 6.6.
Intravenous injection
The dose should be administered over at least 1-5 minutes, depending on the total dose. In haemodialysed patients, a bolus injection may be given during the dialysis session through a suitable venous port in the dialysis line. Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
A slower injection is preferable in patients who react to the treatment with “flu-like” symptoms.
Retacrit should not be administered by intravenous infusion.
Retacrit must not be mixed with other medicinal products (see section 6.2).
Subcutaneous injection
A maximum volume of 1 ml at one injection site should generally not be exceeded. In case of larger volumes, more than one site should be chosen for the injection.
The injections are given in the limbs or the anterior abdominal wall.
4.3 Contraindications
− Hypersensitivity to the active substance or to any of the excipients.
− Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin must not receive Retacrit or any other erythropoietin (see section 4.4).
− Uncontrolled hypertension.
− In the indication "increasing the yield of autologous blood": myocardial infarction or stroke in the month preceding treatment, unstable angina pectoris, increased risk of deep venous thrombosis such as history of venous thromboembolic disease.
− In the indication of major elective orthopaedic surgery: severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
− Patients who for any reason cannot receive adequate antithrombotic prophylaxis.
4.4 Special Warnings And Precautions For Use
General
Like in all patients receiving erythropoietin, blood pressure may rise during treatment with Retacrit. Blood pressure should be closely monitored and adequately controlled in all epoetin treatment naïve as well as pre-treated patients before, at initiation of, and during treatment with Retacrit. It may be necessary to add or increase anti-hypertensive treatment. If blood pressure cannot be well controlled, Retacrit treatment should be discontinued.
Retacrit should also be used with caution in the presence of epilepsy and chronic liver failure.
There may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with erythropoietin. This regresses during the course of continued therapy. It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy.
All other causes of anaemia (iron deficiency, haemolysis, blood loss, vitamin B12
− iron supplementation, e.g. 200-300 mg/day orally (100-200 mg/day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ml
− oral iron substitution of 200-300 mg/day is recommended for all cancer patients whose transferrin saturation is below 20%.
All of these additive factors of anaemia should also be carefully considered when deciding to increase the dose of erythropoietin in cancer patients.
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing. Cases have been reported in patients with hepatits C treated with interferon and ribavirin, when epoetins are used concomitantly. Epoetins are not approved in the management of anaemia associated with hepatitis C.
In order to improve the traceability of ESAs, the name of the prescribed ESA should be clearly recorded (or: stated) in the patient file.
Good blood management practices should always be used in the perisurgical setting.
This medicinal product contains phenylalanine which may be harmful for people with phenylketonuria.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'.
Patients scheduled for major elective orthopaedic surgery
In patients scheduled for major elective orthopaedic surgery the cause of anaemia should be established and treated, if possible, before the start of Retacrit treatment.
Thrombotic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be derived from the treatment.
Patients should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease. In addition, special precaution should be taken in patients with predisposition for development of DVTs. Moreover, in patients with a baseline haemoglobin of> 13 g/dl, the possibility that Retacrit treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. Therefore, it should not be used in patients with baseline haemoglobin> 13 g/dl.
Chronic renal failure patients
Haemoglobin concentration
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death, serious cardiovascular events or cerebrovascular events including stroke were observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Controlled clinical trials have not shown significant benefits attributable to the administration of epoetins when haemoglobin concentration is increased beyond the level necessary to control symptoms of anaemia and to avoid blood transfusion.
Haemoglobin levels should be measured on a regular basis until a stable level is achieved and periodically thereafter. The rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimize the risk of developing or worsening of hypertension.
Chronic renal failure patients treated with Retacrit by the subcutaneous route should be monitored regularly for loss of efficacy, defined as absent or decreased response to Retacrit treatment in patients who previously responded to such therapy. This is characterised by a sustained decrease in haemoglobin despite an increase in Retacrit dosage.
Non response to erythropoietin therapy should prompt a search for causative factors. These include: iron, folate, or Vitamin B12 deficiency; aluminium intoxication; intercurrent infections; inflammatory or traumatic episodes; occult blood loss; haemolysis, and bone marrow fibrosis of any origin.
Cases of antibody-mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route. In patients developing sudden lack of efficacy, defined by a decrease in haemoglobin (1-2 g/dl per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e.g. iron, folate, or Vitamin B12
If PRCA is diagnosed, therapy with Retacrit must be immediately discontinued and testing for erythropoietin antibodies should be considered. Patients should not be switched to another medicinal product as anti-erythropoietin antibodies cross-react with other erythropoietins. Other causes of PRCA should be excluded, and appropriate therapy initiated.
Monitoring of reticulocyte count on a regular basis is recommended to detect possible occurrence of lack of efficacy in chronic renal failure patients.
Hyperkalaemia has been observed in isolated cases. In chronic renal failure patients, correction for anaemia may lead to increased appetite, and potassium and protein intake. Dialysis prescriptions may have to be adjusted periodically to maintain urea, creatinine and potassium in the desired range. Serum electrolytes should be monitored in chronic renal failure patients. If an elevated (or rising) serum potassium level is detected then consideration should be given to ceasing erythropoietin administration until hyperkalaemia has been corrected.
An increase in heparin dose during haemodialysis is frequently required during the course of therapy with erythropoietin as a result of the increased packed cell volume. Occlusion of the dialysis system is possible if heparinisation is not optimum.
Based on information available to date, correction of anaemia with erythropoietin in adult patients with renal insufficiency not yet undergoing dialysis does not accelerate the rate of progression of renal insufficiency.
Adult cancer patients with symptomatic anaemia receiving chemotherapy
In cancer patients receiving chemotherapy, the 2-3 week delay between erythropoietin administration and the appearance of erythropoietin-induced red cells should be taken into account when assessing if Retacrit therapy is appropriate (patient at risk of being transfused).
Haemoglobin levels should be closely monitored until a stable level is achieved and periodically thereafter. If the rate of increase in haemoglobin exceeds 2 g/dl (1.25 mmol/l) per month or the haemoglobin level exceeds 12 g/dl (7,5 mmol/l), the dose adjustment detailed in section 4.2 should be thoroughly performed to minimise the risk of thrombotic events (see section 4.2).
As an increased incidence of thrombotic vascular events (TVEs) has been observed in cancer patients receiving erythropoietic agents (see section 4.8), this risk should be carefully weighed against the benefit to be derived from treatment (with Retacrit) particularly in cancer patients with an increased risk of thrombotic vascular events, such as obesity and patients with a prior history of TVEs (e.g. deep venous thrombosis or pulmonary embolism).
Adult surgery patients in an autologous predonation programme
All special warnings and precautions associated with autologous predonation programs, especially routine volume replacement, should be respected.
Tumour growth potential
Epoetins are growth factors that primarily stimulate red blood cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells. As with all growth factors, there is a concern that epoetins could stimulate the growth of any type of malignancy. In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer.
Several controlled clinical studies in which epoetins were administered to patients with a variety of common tumours including squamous head and neck cancer, lung cancer, and breast cancer, have shown an unexplained excess mortality.
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown:
• shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l),
• shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5 -8.7 mmol/l),
• increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for use in this patient population.
In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer. The decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context. Factors that should be considered in this assessment should include the type of tumour and its stage; the degree of anaemia; life-expectancy; the environment in which the patient is being treated; and patient preference (see section 5.1).
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
There is no evidence to indicate that treatment with erythropoietin alters the metabolism of other medicinal products.
However, since ciclosporin is bound by red blood cells there is potential for interactions with other medicinal products. If erythropoietin is given concomitantly with ciclosporin, blood levels of ciclosporin should be monitored and the dose of ciclosporin adjusted as the haematocrit rises.
No evidence exists that indicates an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimens in vitro.
4.6 Pregnancy And Lactation
There are no adequate and well-controlled studies in pregnant women. Studies in animals have shown reproduction toxicity (see section 5.3). Consequently, erythropoietin should generally be used during pregnancy and lactation only if the potential benefit outweighs the potential risk to the foetus.
4.7 Effects On Ability To Drive And Use Machines
Retacrit has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable Effects
Retacrit is a biological medicinal product. Data from clinical studies with Retacrit are in line with the safety profile of other authorized erythropoietins. Based on the results from clinical trials with other authorized erythropoietins approximately 8% of patients treated with erythropoietin are expected to experience adverse reactions. Undesirable effects during treatment with erythropoietin are observed predominantly in patients with chronic renal failure or underlying malignancies. These undesirable effects are most commonly headache and a dose dependent increase in blood pressure. Hypertensive crisis with encephalopathy-like symptoms can occur. Attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
Antibody-mediated erythroblastopenia (PRCA) has been reported after months to years of treatment with epoetin alfa. In most of these patients, antibodies to erythropoietins have been observed (see sections 4.3 and 4.4).
In this section frequencies of undesirable effects are defined as follows: Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000), not known (frequency cannot be estimated from the available data).
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
| ||
|
| |
| ||
| ||
|
| |
|
| |
| ||
| ||
|
|
|
|
|
|
| ||
|
|
|
| ||
|
| |
| ||
| ||
| ||
|
|
|
|
| |
|
|
|
|
| |
|
| |
|
|
|
|
| |
|
|
|
| ||
| ||
|
| |
| ||
| ||
|
|
|
Adult and paediatric haemodialysis patients, adult peritoneal dialysis patients and adult patients with renal insufficiency not yet undergoing dialysis
The most frequent adverse reaction during treatment with epoetin alfa is a dose-dependent increase in blood pressure or aggravation of existing hypertension. These increases in blood pressure can be treated with medicinal products. Moreover, monitoring of the blood pressure is recommended particularly at the start of therapy. The following reactions have also occurred in isolated patients with normal or low blood pressure: hypertensive crisis with encephalopathy-like symptoms (e.g. headaches and confused state) and generalised tonoclonal seizures, requiring the immediate attention of a physician and intensive medical care. Particular attention should be paid to sudden stabbing migraine like headaches as a possible warning signal.
Shunt thromboses may occur, especially in patients who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurysms, etc.). Early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid, for example, is recommended in these patients.
Adult cancer patients with symptomatic anaemia receiving chemotherapy
Hypertension may occur in epoetin alfa treated patients. Consequently, haemoglobin and blood pressure should be closely monitored.
An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.
Surgery patients
Independent of erythropoietin treatment, thrombotic and vascular events may occur in surgical patients with underlying cardiovascular disease following repeated phlebotomy. Therefore, routine volume replacement should be performed in such patients.
In patients with a baseline haemoglobin of> 13 g/dl, the possibility that Retacrit treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded.
4.9 Overdose
The therapeutic margin of erythropoietin is very wide. Overdose of erythropoietin may produce effects that are extensions of the pharmacological effects of the hormone. Phlebotomy may be performed if excessively high haemoglobin levels occur. Additional supportive care should be provided as necessary.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: Antianaemic preparations, erythropoietin
ATC code: B03XA01
Retacrit is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Erythropoietin is a glycoprotein that stimulates, as a mitosis-stimulating factor and differentiating hormone, the formation of erythrocytes from precursors of the stem cell compartment.
The apparent molecular weight of erythropoietin is 32,000-40,000 Dalton. The protein moiety of the molecule contributes about 58% of total molecular weight and consists of 165 amino acids. The four carbohydrate chains are attached via three N-glycosidic bonds and one O-glycosidic bond to the protein. Epoetin zeta is identical in its amino acid sequence and similar in carbohydrate composition to endogenous human erythropoietin that has been isolated from the urine of anaemic patients.
The biological efficacy of erythropoietin has been demonstrated in various animal models in vivo (normal and anaemic rats, polycythaemic mice). After administration of erythropoietin, the number of erythrocytes, the Hb values and reticulocyte counts increase as well
No comments:
Post a Comment